Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
15.57 USD | -1.02% | -3.40% | 0.00% |
Apr. 15 | Leerink Partners Starts LENZ Therapeutics With Outperform Rating, $32 Price Target | MT |
Apr. 15 | William Blair Starts LENZ Therapeutics With Outperform Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
0.00% | 402M | |
+5.43% | 109B | |
+11.07% | 105B | |
-0.38% | 22.25B | |
-12.19% | 22.09B | |
-7.66% | 18.68B | |
-36.52% | 17.58B | |
-10.41% | 16.85B | |
+2.85% | 13.76B | |
+35.12% | 12.46B |
- Stock Market
- Equities
- LENZ Stock
- News LENZ Therapeutics, Inc.
- Piper Sandler Initiates LENZ Therapeutics at Overweight With $28 Price Target